Earnings Ahead

PRTK - Paratek Pharmaceuticals, Inc.

2.23 0.04 1.83

  1. Home
  2. Healthcare
  3. PRTK
Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc.

About

Profile

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, govern

Headquarters

Boston, Massachusetts, United States

Intraday

High
-
Low
-

52-week

High
-
Low
-

PRTK



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Paratek Pharmaceuticals GAAP EPS of -$0.35 beats by $0.03, revenue of $31.24M misses by $0.39M
  • Paratek Pharmaceuticals Q1 2023 Earnings Preview
  • Paratek a new buy at Jefferies on growing antibiotics business
  • Paratek Pharmaceuticals shares purchased by Highland Capital Management
  • Paratek Pharmaceuticals up 20% on takeout speculation - report
  • Paratek Pharmaceuticals GAAP EPS of -$0.13 misses by $0.23, revenue of $75.6M beats by $12.13M
  • Paratek stock slumps ~25% despite Q4 revenue beat as FY23 sales outlook below estimates
  • Paratek Pharmaceuticals FY 2022 Earnings Preview
  • Paratek/ Zai Lab antibiotic added for reimbursement in China
  • Paratek's treatment for pulmonary anthrax shows promise in study
  • Paratek Pharmaceuticals GAAP EPS of -$0.38, revenue of $30.2M
  • Paratek Pharmaceuticals Q3 2022 Earnings Preview
  • Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
  • Paratek Pharmaceuticals Q2 2022 Earnings Preview
  • Paratek Pharmaceuticals stock soars postmarket on fast track designation for Nuzyra
  • Paratek Pharmaceuticals GAAP EPS of -$0.35 in-line, revenue of $24.86M misses by $2.29M
  • Paratek Pharmaceuticals Q1 2022 Earnings Preview
  • Paratek Pharmaceuticals GAAP EPS of -$1.22 misses by $0.31, revenue of $130.16M misses by $3.57M
  • Paratek, Zai Labs up on Chinese approval of Nuzyra for pneumonia, skin infections
  • Paratek Pharmaceuticals rises 6% after Q3 2021 earnings beat
PEERS
/XLV

XLV

Earnings History

Date EPS / Forecast Revenue / Forecast
November 8, 2021 -0.37 / -0.4501 24.4M / 23.82M Beat!
August 9, 2021 0.2 / 0.3575 57.49M / 58.01M
May 17, 2021 -0.39 / -0.5633 16.43M / 16.53M
May 5, 2021 - / -0.34 - / 18.1M
February 24, 2021 -0.54 / -0.475 16.02M / 16.2M
November 5, 2020 -0.46 / -0.61 13.66M / 11.89M Beat!
August 10, 2020 -0.53 / -0.07 9.33M / 38.04M
May 11, 2020 -0.66 / -0.8 7.3M / 7.46M
February 25, 2020 -0.81 / -1.04 8.97M / 5.43M Beat!
Date Price Open High Low Vol Change ER
May 23, 2023 1.88 1.91
1.98
1.87
120K -1.57%
May 22, 2023 1.91 1.85
1.96
1.85
228K 4.95%
May 19, 2023 1.82 1.87
1.93
1.75
308K -3.19%
May 18, 2023 1.88 1.89
1.91
1.83
144K -0.53%
May 17, 2023 1.89 1.84
1.9
1.78
221K 3.28%
 
May 16, 2023 1.83 1.95
1.95
1.78
299K -6.15%
May 15, 2023 1.95 1.93
2
1.9
244K 2.09%
May 12, 2023 1.91 1.84
1.96
1.8
359K 4.95%
May 11, 2023 1.82 1.85
1.9
1.8
209K -2.67%
May 10, 2023 1.87 1.7
1.94
1.61
554K 10.65%
May 9, 2023 1.69 1.72
1.79
1.61
399K -6.11%
May 8, 2023 1.8 1.77
1.86
1.71
446K 3.45%
May 5, 2023 1.74 1.65
1.76
1.6
515K 10.13%
May 4, 2023 1.58 1.62
1.63
1.57
494K -5.39%
May 3, 2023 1.67 1.56
1.73
1.56
1.0M 7.74%
May 2, 2023 1.55 1.59
1.62
1.55
289K -1.9%
May 1, 2023 1.58 1.6
1.64
1.54
222K -0.63%
Apr 28, 2023 1.59 1.53
1.62
1.45
448K 4.61%
Apr 27, 2023 1.52 1.6
1.6
1.5
473K -5%
Apr 26, 2023 1.6 1.7
1.72
1.54
614K -5.33%
Apr 25, 2023 1.69 1.85
1.9
1.68
770K -8.15%
Apr 24, 2023 1.84 2.39
2.45
1.83
1.9M -26.1%
Apr 21, 2023 2.49 2.27
2.53
2.27
313K 9.69%
Apr 20, 2023 2.27 2.41
2.47
2.19
590K -6.97%
Apr 19, 2023 2.44 2.49
2.51
2.43
391K -2.4%
Apr 18, 2023 2.5 2.7
2.7
2.5
423K -7.06%
Apr 17, 2023 2.69 2.78
2.8
2.63
445K -1.1%
Apr 14, 2023 2.72 2.67
2.78
2.65
261K -0.37%
Apr 13, 2023 2.73 2.75
2.81
2.67
244K -0.36%
Apr 12, 2023 2.74 2.58
2.77
2.58
489K 4.98%
Apr 11, 2023 2.61 2.55
2.73
2.54
550K 1.56%
Apr 10, 2023 2.57 2.6
2.63
2.46
368K -3.02%
Apr 6, 2023 2.65 2.59
2.74
2.54
433K -0.75%
Apr 5, 2023 2.67 2.74
2.74
2.41
931K -2.2%
Apr 4, 2023 2.73 2.78
2.81
2.5
1.0M -2.5%
Apr 3, 2023 2.8 2.62
2.91
2.55
2.6M 10.24%
Mar 31, 2023 2.54 2.58
2.8
2.38
5.8M 19.81%
Mar 30, 2023 2.12 2.08
2.18
2.01
613K 8.72%
Mar 29, 2023 1.95 1.9
1.99
1.84
432K 1.04%
Mar 28, 2023 1.93 1.86
1.97
1.85
344K 2.12%
Mar 27, 2023 1.89 1.7
1.93
1.67
515K 14.55%
Mar 24, 2023 1.65 1.69
1.71
1.62
465K -2.37%
Mar 23, 2023 1.69 1.83
1.83
1.67
559K -6.11%
Mar 22, 2023 1.8 1.73
1.81
1.59
2.2M -3.23%
Mar 21, 2023 1.86 1.45
1.92
1.37
7.0M 35.77%
Mar 20, 2023 1.37 1.6
1.6
1.34
612K -11.04%
Mar 17, 2023 1.54 1.48
1.55
1.45
903K 4.05%
Mar 16, 2023 1.48 1.69
1.7
1.29
3.4M -22.51%
Mar 15, 2023 1.91 1.91
2
1.87
294K -2.05%
Mar 14, 2023 1.95 1.96
1.99
1.77
775K 10.80%
Mar 13, 2023 1.76 1.66
1.76
1.64
252K 6.02%
Mar 10, 2023 1.66 1.68
1.68
1.59
411K -1.78%
Mar 9, 2023 1.69 1.78
1.79
1.66
233K -5.06%
Mar 8, 2023 1.78 1.87
1.91
1.78
135K -5.32%
Mar 7, 2023 1.88 1.92
1.96
1.87
183K -2.08%
Mar 6, 2023 1.92 1.81
1.94
1.8
242K 7.26%
Mar 3, 2023 1.79 1.77
1.81
1.77
106K 1.13%
Mar 2, 2023 1.77 1.76
1.79
1.74
88.0K 0%
Mar 1, 2023 1.77 1.75
1.78
1.74
105K 1.14%
Feb 28, 2023 1.75 1.76
1.76
1.7
132K 0%